Ignite Creation Date:
2024-05-05 @ 12:11 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00264290
Status:
COMPLETED
Last Update Posted:
2020-07-31
First Post:
2005-12-09
Brief Title:
Valganciclovir to Reduce T Cell Activation in HIV Infection
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Study Overview
Official Title:
Valganciclovir to Reduce T Cell Activation in HIV Infection
Status:
COMPLETED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether treatment with valganciclovir decreases T cell activation levels among HIV-infected patients with asymptomatic cytomegalovirus CMV co-infection potentially improving immune responses to antiretroviral therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Roche VAL 104 | None | None | None |
| SFGH GCRC 976 | None | None | None |
| 5 P30 AI 27763 - Hunt | None | None | None |